Sensitivity of camptothecin-resistant human leukemia cells and tumors to anticancer drugs with diverse mechanisms of action

Leukemia Research

Volumn 19, Issue 1, 1995, Pages 43-55

  Pantazis, Panayotis ^a   Vardeman, Dana ^a   Mendoza, John ^a   Early, Janet ^a   Kozielski, Anthony ^a   DeJesus, Albert ^a   Giovanella, Beppino ^a  

^a St Joseph's Medical Center Houston   (United States)

Author keywords

apoptosis; cell cycle; flow cytometry; nude mouse; Topoisomerase

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARMUSTINE; CYTARABINE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; METHOTREXATE; NITROSOUREA; VINCRISTINE;

ANIMAL EXPERIMENT; ARTICLE; CELL CLONE; CONTROLLED STUDY; DIPLOIDY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANIMAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CELL CYCLE; CELL DIVISION; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DRUG RESISTANCE; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMAN; LEUKEMIA; MALE; MICE; MICE, NUDE; SUPPORT, NON-U.S. GOV'T;

EID: 0028796774     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(94)00060-N     Document Type: Article

References (56)

1. Biochemistry of DNA topoisomerases and their poisons
2. DNA topoisomerases as targets of therapeutics: a structural overview
3. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures
4. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
5. Studies on therapeutic effectiveness of drugs with tumor weight and survival time indices of Walker 256 carcinosarcoma
6. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II
7. Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemia cells
8. Camptothecin, teniposide or 4′-(9-acridinyl-amino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells
9. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin
10. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells
11. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice by camptothecins
12. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells
13. The current status of camptothecin analogues as antitumor agents
14. Topoisomerase I inhibitors: promising novel compounds
15. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro
16. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between nontumorigenic and tumorigenic cells in vitro
17. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro
18. DNA topoisomerase poisons as antitumor drugs
19. Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes
20. cdc2/cyclin B
21. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription
22. Rapid induction of c-fos transcription reveals quantitative linkage of RNA polymerase II and DNA topoisomerase I enzyme activities
23. Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells
24. Induction of differentiation of human and mouse myeloid leukemia cells by camptothecin
25. Studies of the differentiation properties of camptothecin in the human leukaemic cells K562
26. Apoptotic process in the variation-induced death of lymphocytes
27. Cell injury and death
28. Characterization of camptothecin-resistant Chinese hamster lung cells
29. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance
30. Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons
31. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line
32. Therapeutic efficacy of camptothecin-derivatives against human malignant melanoma xenografts
33. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts
34. Establishment and characterization of a human hystiocytic lymphoma cell line (U-937)
35. DNA ploidy and cell cycle analysis
36. Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry
37. Features of apoptotic cells by flow cytometry
38. The use of flow cytometry for the investigation of cell death
39. Miscellaneous applications of flow cytometry
40. 9-nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro
41. Decreased expression of topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody
42. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation
43. A phase I study of oral therapy of human tumors with 20-(S)-camptothecin
44. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content
45. Establishment of a camptothecin analogue (CPT-11) resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance
46. Characterization of a camptothecin-resistant human DNA topoisomerase
47. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture
48. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine
49. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin
50. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance
51. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors
52. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines
53. Cloning, characterization, and sequence of the yeast DNA topoisomerase I gene
54. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-β-d-arabinofuranosylcytosine